new glp-1 drug From 'companion foods' to 'Nature's Ozempic.' Big food & GLP-1 Drugs: 6 Things We've

GLP-1 receptor agonists and GLP-1/GIP combination therapies have become foundational treatments for type 2 diabetes and obesity

[DOI] [PubMed] [Google Scholar] 825.Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M

From the FDA approval of the first GLP-1RA drug to the approval of oral semaglutide today, GLP-1RA has undergone several iterations

Uterine cancer was significantly reduced in the GLP1RA arm in trials performed in subjects with obesity (MHOR 0.24, 95% CI [0.06, 0.94]), but not in those aimed at diabetes treatment (MHOR 0.92, [0.58, 1.47])

Clinicians must navigate administrative processes that require detailed documentation, justification, and, in some cases, repeated submissions

Notably, evidence from whole-body Glp1r knockout mice, discussed elsewhere in this Review, suggests that endogenous GLP-1R signaling plays a critical role in modulating inflammation, highlighting the need for further investigation